| 摘要 |
PURPOSE: To treat a higher mammalian having osteoporosis in cortex or being in a dangerous state generating the osteoporosis by administering an insulin-like growth factor I (IGF-I). CONSTITUTION: This method is to treat prevent osteoporosis in a higher mammalian by administering an affective amount of a compound selected from IGF-I, its active fragment, its active analogue, or an active fragment of either one of IGF-I and its active analogue to a higher mammalian exhibiting a decreased cortex inorganic substance density, a higher mammalian exposed to a medicine or environmental state liable to cause the decrease in the cortex inorganic substance density or a higher mammalian potentially having liability causing the cortex osteoporosis state. The IGF-I is preferably produced by genetic recombination technology, and is preferably administered by a parenteral (intravenous, hypodermic or intramuscular) administration method at a daily dose of 2.5-180μg/kg, especially 10-90μg/kg.
|
